Erythropoietin in Traumatic Brain Injury: An Answer Will Come Soon

Giovanni Grasso, Concetta Alafaci, Michele Buemi

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

Traumatic brain injury (TBI) is a major cause of morbidity and mortality in the United States. It is estimated that each year TBIs are associated with 1.1 million emergency department visits, 235,000 hospitalizations, and 50,000 deaths (1). Despite improvements in medical interventions, there are still no neuroprotective agents available to counteract secondary or delayed damage to the traumatically injured human brain or to promote its repair. TBI encompasses heterogeneous etiologic, anatomical, and molecular patterns of injury that exhibit different propensities to cause cerebral damage. Without careful consideration of individual injuries, the results of therapeutic trials remain difficult to interpret.
Original languageEnglish
Pages (from-to)1491-1492
Number of pages2
JournalWorld Neurosurgery
Volume84
Publication statusPublished - 2015

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Erythropoietin in Traumatic Brain Injury: An Answer Will Come Soon'. Together they form a unique fingerprint.

Cite this